Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2004-08-24
2008-08-05
Peselev, Elli (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C536S007200
Reexamination Certificate
active
07407941
ABSTRACT:
Compounds having the structure of formula Iwherein R1, R2, R3, R4, R5, and R6are as defined herein, are prokinetic agents and can be used to treat disorders of gastric motility.
REFERENCES:
patent: 3681323 (1972-08-01), Kurath et al.
patent: 3681325 (1972-08-01), Freiberg
patent: 4670549 (1987-06-01), Morimoto et al.
patent: 4948782 (1990-08-01), Omura et al.
patent: 5008249 (1991-04-01), Omura et al.
patent: 5175150 (1992-12-01), Omura et al.
patent: 5190871 (1993-03-01), Cox et al.
patent: 5470961 (1995-11-01), Harada et al.
patent: 5523401 (1996-06-01), Freiberg et al.
patent: 5523418 (1996-06-01), Freiberg et al.
patent: 5538961 (1996-07-01), Freiberg et al.
patent: 5554605 (1996-09-01), Freiberg et al.
patent: 5578579 (1996-11-01), Lartey et al.
patent: 5654411 (1997-08-01), Lartey et al.
patent: 5658888 (1997-08-01), Koga et al.
patent: 5712253 (1998-01-01), Lartey et al.
patent: 5824513 (1998-10-01), Katz et al.
patent: 5830750 (1998-11-01), Khosla et al.
patent: 5834438 (1998-11-01), Lartey et al.
patent: 5854407 (1998-12-01), Harada et al.
patent: 5922849 (1999-07-01), Premchandran et al.
patent: 5959088 (1999-09-01), Miura et al.
patent: 6077943 (2000-06-01), Omura et al.
patent: 6084079 (2000-07-01), Keyes et al.
patent: 6177262 (2001-01-01), Ziermann et al.
patent: 6251636 (2001-06-01), Betlach et al.
patent: 6303767 (2001-10-01), Betlach et al.
patent: 6395710 (2002-05-01), Chu et al.
patent: 6399582 (2002-06-01), Hlasta et al.
patent: 6399789 (2002-06-01), Santi et al.
patent: 6403775 (2002-06-01), McDaniel
patent: 6451768 (2002-09-01), Chu
patent: 6458771 (2002-10-01), Hlasta et al.
patent: 6503741 (2003-01-01), Ashley et al.
patent: 6514944 (2003-02-01), Chu
patent: 6524841 (2003-02-01), McDaniel et al.
patent: 6562795 (2003-05-01), Ashley et al.
patent: 6590083 (2003-07-01), Hlasta et al.
patent: 6750205 (2004-06-01), Ashley et al.
patent: 6946482 (2005-09-01), Santi et al.
patent: 2002/0004229 (2002-01-01), Santi et al.
patent: 2002/0025936 (2002-02-01), Ashley et al.
patent: 2002/0094962 (2002-07-01), Ashley et al.
patent: 2002/0192709 (2002-12-01), Carreras et al.
patent: 1314737 (2003-05-01), None
patent: 1319216 (1973-06-01), None
patent: 60-218321 (1985-11-01), None
patent: 08-231580 (1996-09-01), None
patent: WO 00/01827 (2000-01-01), None
patent: WO 01/60833 (2001-08-01), None
patent: WO 03/090679 (2003-11-01), None
patent: WO 2004/013153 (2004-02-01), None
Burger's Medicinal Chemistry and Drug Discovery, 5th edition, vol. I, Manfred E. Wolff, 1995, pp. 975-977.
Modern Pharmacuetics, 3rd edition, Banker et al., 1995, pp. 596.
U.S. Appl. No. 10/648,946, filed Aug. 26, 2003, Santi et al.
U.S. Appl. No. 10/925,709, filed Aug. 24, 2004, Carreras et al.
Carreras et al.,Anal. Biochem., 300, 146-151 (2002), “Stable Expression of a Synthetic Gene for the Human Motilin Receptor: Use in an Aequorin-based Receptor Activation Assay”.
Carreras et al.,J. Biotechnol., 92, 217-228 (2002), “Saccharopolyspora erythraea-catalyzed bioconversion of 6-deoxyerythronolide B analogs for production of novel erythromycins”.
Chemical Abstracts No. 104:82047 (abstract of JP 60-218321).
Chemical Abstracts No. 125:329280 (abstract of JP 08-231580).
Cowles et al.,J. Pharmacol. Exp. Therapeutics, 293 (3), 1106-1111 (2000).
Depoortere et al.,J. Gastrointestinal Motility, 1, 150-159 (1989), “Structure-Activity Relation of Erythromycin-Related Macrolides in Inducing Contractions and in Displacing Bound Motilin in Rabbit Duodenum”.
Faghih et al.,Biorg.&Med. Chem. Lett., 8, 805-810 (1998), “Preparation of 9-Deoxo-4″-deoxy-6,9-epoxyerythromycin Lactams ‘Motilactides’: Potent and Orally Active Prokinetic Agents”.
Faghih et al.,Drugs Future, 23 (8), 861-872 (1998), “Motilides and motilactides: design and development of motilin receptor agonists as a new class of gastrointestinal prokinetic drugs”.
Faghih et al.,J. Med. Chem.41, 3402-3408 (1998), “Synthesis of 9-Deoxo-4″-deoxy-6,9-epoxyerythromycin Derivatives: Novel and Acid-Stable Motilides”.
Faghih et al.,Synlett751 (Jul. 1998), “Entry into Erythromycin Lactams: Synthesis of Erythromycin A Lactam Enol Ether as a Potential Gastrointestinal Prokinetic Agent”.
Frykman et al.,Biotechnol. Bioeng., 76, 303-310 (2001) “Precursor-Directed Production of Erythromycin Analogs bySaccharopolyspora erythraea”.
Hauske et al.,J. Org. Chem., 47, 1595-1596 (1982), “Synthesis of 10,11-Anhydroerythromycin”.
Hauske et al.,J. Org. Chem., 49, 712-714 (1984), “Regiospecific Synthesis of 9-Desoxoerythromycin A”.
Khiat et al.,J. Peptide Res.52, 321-328 (1998), “Identification of the Motilide Pharamacophores Using Quantitative Structure Activity Relationships”.
Lartey et al.,J. Antibiotics, 48 (7), 730-732 (1995), “Stereoselective Deoxygenation of Erythromycin A at C12: Effect of Structure and Conformation on Prokinetic Activity”.
Lartey et al.,J. Med. Chem., 38 (10), 1793-1798 (1995), “Synthesis of 4″-Deoxy Motilides: Identification of a Potent and Orally Active Prokinetic Drug Candidate”.
Omura et al.,J. Antibiotics38, 1631-2 (1985), “Gastrointestinal Motor-Stimulating Activity of Macrolide Antibiotics and the Structure-Activity Relationship”.
Rodriguez et al.,J. Ind. Microbio. Biotechnol., 8, 480-8 (2003), “Rapid Engineering of Polyketide Overproduction by Gene Transfer to Industrially Optimized Strains”.
Steinmetz et al.,J. Med. Chem., 45, 4899-4902 (2002), “Structure of Erythromycin Enol Ether as a Model for Its Activity as a Motilide”.
Sunazuka et al.,Chem. Pharm. Bull., 37 (10), 2701-2709 (1989), “Motilides, Macrolides with Gastrointestinal Motor Stimulating activity. II. QuaternaryN-Substituted Derivatives of 8,9-Anhydroerythrmycin A 6,9-Hemiacetal and 9,9-dihydroerythromycin A 6,9-Epoxide”.
Tsuzuki et al.,Chem. Pharm. Bull., 37 (10), 2687-2700 (1989), “Motilides, Macrolides with Gastrointestinal Motor Stimulating activity. I.O-Substituted and TertiaryN-Substituted Derivatives of 8,9-Anhydroerythromycin A 6,9-Hemiacetal”.
Wermuth, “Designing Prodrugs and Bioprecursors,” in Wermuth, ed.,The Practice of Medicinal Chemistry, 2nd Ed., pp. 561-586 (Academic Press 2003).
Xue et al.,Proc. Natl. Acad. Sci. U.S.A., 96, 11740-11745 (1999), “A multiplasmid approach to preparing large libraries of polyketides”.
Bierman et al.,Gene116, 43-49 (1992), “Plasmid cloning vectors for the conjugal transfer of DNA fromEscherichia colitoStreptomycesspp.”
Carreras Christopher
Liu Yaoquan
Foley & Lardner LLP
Peselev Elli
Pfizer Inc.
LandOfFree
N-desmethyl-N-substituted-11-deoxyerythromycin compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N-desmethyl-N-substituted-11-deoxyerythromycin compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N-desmethyl-N-substituted-11-deoxyerythromycin compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4002592